GlassScriptPhysician profile
Shehzad Aziz
NPI 1295732410
$5,934.85
in general payments reported to CMS, 2019-2025
62 companies · $1,734 in 2025
The $1,734 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $81.68 · 2021: $229 · 2022: $944 · 2023: $1,110 · 2024: $1,531 · 2025: $1,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,041 · Education: $334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,041.46 |
| Education | $333.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $638.68 | 2021-2025 | Darzalex, Talvey, Erleada |
| Daiichi Sankyo INC. | $438.93 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Astrazeneca Pharmaceuticals LP | $424.45 | 2022-2025 | Faslodex, Tagrisso, Lynparza |
| Aveo Pharmaceuticals, INC. | $325.78 | 2021-2025 | Fotivda |
| Novartis Pharmaceuticals Corporation | $284.51 | 2022-2025 | |
| Eisai INC. | $221.53 | 2022-2025 | |
| Pfizer INC. | $213.84 | 2019-2025 | |
| Glaxosmithkline, LLC. | $198.30 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Astellas Pharma US INC | $189.67 | 2019-2025 | Xtandi, Cresemba, Vyloy |
| Gilead Sciences, INC. | $141.71 | 2019-2025 | Trodelvy |
| Genentech USA, INC. | $128.57 | 2019-2025 | Polivy, Tecentriq, Itovebi |
| Springworks Therapeutics, INC. | $121.77 | 2024-2025 | Ogsiveo |
| Amgen INC. | $119.20 | 2019-2023 | Xgeva |
| Takeda Pharmaceuticals U.S.A., INC. | $117.36 | 2024-2025 | Alunbrig, Ninlaro, Fruzaqla |
| Celgene Corporation | $114.87 | 2021-2024 | Reblozyl, Pomalyst |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shehzad Aziz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.